Migraine headaches strike roughly 12% of the world's population at least once per year. Existing treatments can only head off migraines after they start, and don't work for many people. However, four pharmaceutical companies are working on a new class of drugs that many scientists believe can stop migraines at their root. They're conducting advanced clinical trials of antibody drugs that block the activity of a molecule called calcitonin gene-related peptide, or CGRP, which spikes during migraine attacks. The discovery of CGRP may also help to solve the centuries-old puzzle of what triggers a migraine's complex neurological events.
http://news.sciencemag.org/brain-behavior/2016/01/feature-will-antibodies-finally-put-end-migraines
http://news.sciencemag.org/brain-behavior/2016/01/feature-will-antibodies-finally-put-end-migraines